Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells

Inflammation Research

Volumn 46, Issue 2, 1997, Pages 51-59

  Wong, E ^a   DeLuca, C ^a   Boily, C ^a   Charleson, S ^a   Cromlish, W ^a   Denis, D ^a   Kargman, S ^a   Kennedy, B P ^a   Ouellet, M ^a   Skorey, K ^a   O'Neill, G P ^a   Vickers, P J ^a,b   Riendeau, D ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Cyclooxygenase; Inflammation; NSAIDs; Prostaglandin; Prostaglandin H synthase

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ARACHIDONIC ACID; DEXAMETHASONE; DICLOFENAC; ENZYME INHIBITOR; ETODOLAC; FLOSULIDE; FLURBIPROFEN; INDOMETACIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC SULFIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; ISOMER; OSTEOSARCOMA CELL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; DEXAMETHASONE; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; OSTEOSARCOMA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 8044259636     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050063     Document Type: Article

References (47)

1. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Sem Nephrol 1995;15:179-94.
2. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
3. Xie W, Robertson DL, Simmons DL. Mitogen-inducihle prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs. Drug Development Res 1992;25:249-65.
4. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-40.
5. Percival MD, Ouellet M, Vincent C, Yergey J, Kennedy BP, O'Neill GP. Purification and characterization of recombinant human cyclooxygenase-2. Arch Biochem Biophys 1994;315: 111-8.
6. Battistini B, Botting R, Bakhle YS. COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect 1994;7:501-12.
7. O'Neill GP, Mancini JA, Kargman S, et al. Overexpression of prostaglandin G/H synthases-1 and -2 by recombinant vaccinia virus:inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 1994;45:245-54.
8. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
9. Griswold DE, Adams JL. Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date. Med Res Rev 1996;16:181-206.
10. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
11. Chan C-C, Boyce S, Brideau C, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal antiinflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Therap 1996;274:1531-7.
12. Kennedy BP, Chan C-C, Culp S, Cromlish W. Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem Biophys Res Commun 1993;197: 494-500.
13. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
14. Futaki N, Yoshikawa K, Hamasaka Y, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmac 1993;24:105-10.
15. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
16. Engelhardt G, Bogel R, Schnitzler C, Utzmann R. Meloxicam: Influence on Arachidonic Acid Metabolism. Part 1. In Vitro findings. Biochem Pharmacol 1996;51:21-8.
17. Grossmann CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuelear cells by NSAIDS and COX 2 inhibitors. Inflamm Res 1995;44:253-7.
18. Klein T, Nusing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:1605-10.
19. Gans KR, Galbraith W, Roman RJ, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990;254:180-7.
20. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-9.
21. Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-11.
22. Cromlish WA, Kennedy BP, O'Neill G, Vickers PJ, Wong E, Mancini JA. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity. International Patent Application WO 9414977, 1994.
23. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for Cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-60.
24. Kargman S, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-9.
25. Ouellet M, Percival MD. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 1995;306:247-51.
26. Copeland RA, Williams JM, Giannaras J, et al. Mechanism of selective inhibition of the inducible isoform or prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994;91:11202-6.
27. Zhang W, Dziak R. Effects of interleukin-1α on arachidonic acid metabolism in human osteosarcoma osteoblastic cells. Prostagland Leukotr Essential Fatty Acids 1993;49:521-6.
28. de Brum-Fernandes AJ, Laporte S, Heroux M, et al. Expression of prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 in human osteoblasts. Biochem Biophys Res Commun 1994;198:955-60.
29. Pilbeam CC, Kawaguchi H, Voznesensky O, Alander CB, Raisz LG. Differential Regulation of Inducible and Constitutive Prostaglandin Endoperoxide Synthase in Osteoblastic MC3T3-E1 Cells. J Biol Chem 1993;268:25643-9.
30. Takahashi Y, Taketani Y, Endo T, Yamamoto S, Kumegawa M. Studies on the induction of cyclooxygenase isozymes by various prostaglandins in mouse osteoblastic cell line with reference to signal transduction pathways. Biochim Biophys Acta 1994;1212:217-24.
31. 2 in Rat Zymosan-Induced Pleurisy. J Biochem 1993;114:509-12.
32. 1 Cells. J Biol Chem 1993;268:21875-82.
33. 2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis. J Biol Chem 1994;269:25999-6005.
34. 2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Arthritis & Rheumatism 1994;37:653-61.
35. 2 and cyclooxygenase-2. Eur J Biochem 1994;226:125-31.
36. 2 in human amnion-derived WISH cells. Prostaglandins 1995;49:351-69.
37. Riendeau D, Guay J, Weech PK, et al. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem 1994;269:15619-24.
38. 2 inhibit release of free arachidonate in thrombin-stimulated human platelets. J Biol Chem 1994;269:L5625-30.
39. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk C, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Therap 1995;271:927-34.
40. Barnett J, Chow J, Ives D, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994;1209:130-9.
41. 2 in mouse bone marrow-derived mast cells. J Biol Chem 1994;269:22269-75.
42. Reddy S, Herschman HR. Ligand-induced prostaglandin synthesis requires expression of the TIS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 1994;269:15473-80.
43. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-86.
44. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-10.
45. Kelly RW. Pregnancy maintenance and parturition: The role of prostaglandin in manipulating the immune and inflammatory response. Endocrine Rev 1994;15:684-706.
46. Sirois J, Levy LO, Simmons DL, Richards JS. Characterization and Hormonal Regulation of the Promoter of the Rat Prostaglandin Endoperoxide Synthase 2 Gene in Granulosa Cells. J Biol Chem 1993;268:12199-206.
47. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.